Multidimensional protein fractionation using ProteomeLab PF 2D for profiling amyotrophic lateral sclerosis immunity: A preliminary report.
BACKGROUND
The ProteomeLab PF 2D platform is a relatively new approach to global protein profiling. Herein, it was used for investigation of plasma proteome changes in amyotrophic lateral sclerosis (ALS) patients before and during immunization with glatiramer acetate (GA) in a clinical trial.


RESULTS
The experimental design included immunoaffinity depletion of 12 most abundant proteins from plasma samples with the ProteomeLab IgY-12 LC10 column kit as first dimension separation, also referred to as immuno-partitioning. Second and third dimension separations of the enriched proteome were performed on the PF 2D platform utilizing 2D isoelectric focusing and RP-HPLC with the resulting fractions collected for analysis. 1D gel electrophoresis was added as a fourth dimension when sufficient protein was available. Protein identification from collected fractions was performed using nano-LC-MS/MS approach. Analysis of differences in the resulting two-dimensional maps of fractions obtained from the PF 2D and the ability to identify proteins from these fractions allowed sensitivity threshold measurements. Masked proteins in the PF 2D fractions are discussed.


CONCLUSIONS
We offer some insight into the strengths and limitations of this emerging proteomic platform.
Schlautman
Joshua D
JD
Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, USA. jschlautman@unmc.edu
Rozek
Wojciech
W
Stetler
Robert
R
Mosley
R Lee
RL
Gendelman
Howard E
HE
Ciborowski
Pawel
P
J Ind Microbiol Biotechnol. 2006 Nov;33(11):914-20
16964509
Mol Cell Proteomics. 2002 Nov;1(11):845-67
12488461
Mol Cell Proteomics. 2006 Jan;5(1):26-34
16188874
Anal Biochem. 2006 Dec 1;359(1):84-93
17034751
Proteomics. 2006 Oct;6(19):5096-8
16941567
Chem Rev. 2007 Aug;107(8):3601-20
17636887
J Neurol Neurosurg Psychiatry. 2008 Oct;79(10):1190-3
18223021
Proteomics. 2006 Oct;6(20):5385-408
16991193
Physiol Genomics. 2008 Mar 14;33(1):3-11
18162499
Adv Clin Chem. 2007;44:103-42
17682341
Anal Chem. 2003 May 15;75(10):2299-308
12918970
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 15;849(1-2):115-28
17049937
Expert Rev Proteomics. 2007 Jun;4(3):363-70
17552920
Amyotroph Lateral Scler. 2007 Aug;8(4):235-42
17653922
Expert Rev Proteomics. 2007 Feb;4(1):51-65
17288515
Biochim Biophys Acta. 2006 Dec;1764(12):1853-69
17134948
Anal Chem. 2005 May 1;77(9):2745-55
15859589
J Ind Microbiol Biotechnol. 2005 Feb;32(2):75-82
15726440
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 May 5;771(1-2):3-31
12015990
Neurology. 2006 Apr 11;66(7):1117-9
16606934
Mol Psychiatry. 2004 Feb;9(2):128-43
14708031
Mol Cell Proteomics. 2006 Jan;5(1):53-6
16272560
Proteomics. 2006 Feb;6(4):1143-50
16404720
Electrophoresis. 2007 Jun;28(12):1980-8
17503404
Clin Chem Lab Med. 2005;43(12):1327-33
16309368
J Chromatogr A. 2007 Jul 13;1156(1-2):188-95
17276440
J Chromatogr A. 2007 Jun 15;1153(1-2):277-90
17321532
Anal Bioanal Chem. 2005 Jun;382(3):669-78
15900442
Physiol Genomics. 2007 Jun 19;30(1):89-94
17341690
J Chromatogr A. 2007 Jun 15;1153(1-2):259-76
17166507
Expert Rev Proteomics. 2005 Jun;2(3):381-92
16000084
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Sep 1;841(1-2):65-78
16782413
J Proteome Res. 2007 Oct;6(10):4055-62
17877382
Proteomics. 2005 Nov;5(16):4052-61
16196093